Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study

被引:329
作者
Reimer, Peter [1 ]
Ruediger, Thomas
Geissinger, Eva
Weissinger, Florian
Nerl, Christoph
Schmitz, Norbert
Engert, Andreas
Einsele, Hermann
Mueller-Hermelink, Hans Konrad
Wilhelm, Martin
机构
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, D-97070 Wurzburg, Germany
关键词
HIGH-DOSE CHEMOTHERAPY; NON-HODGKINS-LYMPHOMA; DETUDE DES LYMPHOMES; INTERNATIONAL PROGNOSTIC INDEX; FRONT-LINE AUTOTRANSPLANTATION; COMPLETE REMISSION; MARROW TRANSPLANTATION; EUROPEAN GROUP; PHASE-II; PTCL;
D O I
10.1200/JCO.2008.17.4870
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Peripheral T-cell lymphomas (PTCLs) are rare malignancies with poor outcome after conventional chemotherapy. The role of myeloablative therapy and autologous stem-cell transplantation (autoSCT) is still unclear. Therefore, we initiated the first prospective multicenter study on upfront autoSCT in PTCL and recently reported good feasibility and efficacy of this approach. Here, we present the final analysis of the study. Patients and Methods The treatment regimen consisted of four to six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by mobilizing therapy with either the dexamethasone, carmustine, melphalan, etoposide, and cytarabine protocol or the etoposide, methylprednisolone, cytarabine, and cisplatin protocol and stem-cell collection. Patients in complete remission (CR) or partial remission ( PR) underwent myeloablative chemoradiotherapy (fractionated total-body irradiation and high-dose cyclophosphamide) and autoSCT. Results From June 2000 to April 2006, 83 patients were enrolled onto the study. Main subgroups were PTCL not specified (n = 32) and angioimmunoblastic T-cell lymphoma ( n = 27). Fifty-five (66%) of the 83 patients received transplantation. The main reason for not receiving autoSCT was progressive disease. In an intent-to-treat analysis, the overall response rate after myeloablative therapy was 66% (56% CR and 8% PR). With a median follow-up time of 33 months, 43 patients are alive; the estimated 3-year overall and disease-free survival rates for patients in CR ( calculated from CR to the date of relapse) and 3-year progression-free survival rate were 48%, 53%, and 36%, respectively. Conclusion The results of this prospective study suggest a substantial impact on outcome for upfront autoSCT in PTCL and should be further evaluated in randomized trials. Pretransplantation treatment needs to be improved to increase the transplantation rate.
引用
收藏
页码:106 / 113
页数:8
相关论文
共 61 条
  • [1] Predictive capacity of the international prognostic factor index in patients with peripheral T-cell lymphoma
    Ansell, SM
    Habermann, TM
    Kurtin, PJ
    Witzig, TE
    Chen, MG
    Li, CY
    Inwards, DJ
    Colgan, JP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2296 - 2301
  • [2] ARMITAGE JO, 1989, CANCER-AM CANCER SOC, V63, P158, DOI 10.1002/1097-0142(19890101)63:1<158::AID-CNCR2820630125>3.0.CO
  • [3] 2-B
  • [4] CLINICAL-SIGNIFICANCE OF IMMUNOPHENOTYPE IN DIFFUSE AGGRESSIVE NON-HODGKINS LYMPHOMA
    ARMITAGE, JO
    VOSE, JM
    LINDER, J
    WEISENBURGER, D
    HARRINGTON, D
    CASEY, J
    BIERMAN, P
    SORENSEN, S
    HUTCHINS, M
    MORAVEC, DF
    HOWE, D
    DOWLING, MD
    MAILLIARD, J
    JOHNSON, PS
    PEVNICK, W
    PACKARD, WM
    OKERBLOOM, J
    THOMPSON, RF
    LANGDON, RM
    SOORI, G
    PETERSON, C
    PURTILO, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (12) : 1783 - 1790
  • [5] Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the REAL classification
    Ascani, S
    Zinzani, PL
    Gherlinzoni, F
    Sabattini, E
    Briskomatis, A
    deVivo, A
    Piccioli, M
    Orcioni, GF
    Pieri, F
    Goldoni, A
    Piccaluga, PP
    Zallocco, D
    Burrelli, R
    Leoncini, L
    Falini, B
    Tura, S
    Pileri, SA
    [J]. ANNALS OF ONCOLOGY, 1997, 8 (06) : 583 - 592
  • [6] High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas
    Blystad, AK
    Enblad, G
    Kvaloy, S
    Berglund, Å
    Delabie, J
    Holte, H
    Carlson, K
    Kvalheim, G
    Bengtsson, M
    Hagberg, H
    [J]. BONE MARROW TRANSPLANTATION, 2001, 27 (07) : 711 - 716
  • [7] Chan WC, 1997, BLOOD, V89, P3909
  • [8] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
    Cheson, BD
    Horning, SJ
    Coiffier, B
    Shipp, MA
    Fisher, RI
    Connors, JM
    Lister, TA
    Vose, J
    Grillo-López, A
    Hagenbeek, A
    Cabanillas, F
    Klippensten, D
    Hiddemann, W
    Castellino, R
    Harris, NL
    Armitage, JO
    Carter, W
    Hoppe, R
    Canellos, GP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1244 - 1253
  • [9] PERIPHERAL T-CELL LYMPHOMAS HAVE A WORSE PROGNOSIS THAN B-CELL LYMPHOMAS - A PROSPECTIVE-STUDY OF 361 IMMUNOPHENOTYPED PATIENTS TREATED WITH THE LNH-84 REGIMEN
    COIFFIER, B
    BROUSSE, N
    PEUCHMAUR, M
    BERGER, F
    GISSELBRECHT, C
    BRYON, PA
    DIEBOLD, J
    [J]. ANNALS OF ONCOLOGY, 1990, 1 (01) : 45 - 50
  • [10] Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation
    Corradini, P.
    Tarella, C.
    Zallio, F.
    Dodero, A.
    Zanni, M.
    Valagussa, P.
    Gianni, A. M.
    Rambaldi, A.
    Barbui, T.
    Cortelazzo, S.
    [J]. LEUKEMIA, 2006, 20 (09) : 1533 - 1538